Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

ClinicalTrials.gov ID: NCT06956235

Public ClinicalTrials.gov record NCT06956235. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa

Study identification

NCT ID
NCT06956235
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
147 participants

Conditions and interventions

Interventions

  • Tulisokibart Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2025
Primary completion
Nov 15, 2026
Completion
Jan 21, 2029
Last update posted
Jan 19, 2026

2025 – 2029

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Cahaba Dermatology & Skin Health Center ( Site 0012) Birmingham Alabama 35244
Medical Dermatology Specialists ( Site 0027) Phoenix Arizona 85006
Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049) Rogers Arkansas 72758
Northridge Clinical Trials ( Site 0004) Northridge California 91325
Integrative Skin Science and Research ( Site 0015) Sacramento California 95815
Olympian Clinical Research ( Site 0010) Tampa Florida 33615
Skin Care Physicians of Georgia ( Site 0033) Macon Georgia 31217
Dawes Fretzin Clinical Research Group, LLC ( Site 0025) Indianapolis Indiana 46250
Beth Israel Deaconess Medical Center ( Site 0044) Boston Massachusetts 02215
Revival Research Institute, LLC ( Site 0005) Troy Michigan 48084
Mount Sinai Doctors - East 85th Street ( Site 0050) New York New York 10028
DJL Clinical Research, PLLC ( Site 0021) Charlotte North Carolina 28211
University Hospitals Cleveland Medical Center ( Site 0046) Cleveland Ohio 44106
Wright State Physicians Health Center ( Site 0041) Fairborn Ohio 45324
Palmetto Clinical Trial Services, LLC ( Site 0023) Anderson South Carolina 29621
Arlington Center for Dermatology ( Site 0045) Arlington Texas 76011
Texas Dermatology Research Center ( Site 0019) Dallas Texas 75246
Reveal Research Institute ( Site 0018) Frisco Texas 75033
Progressive Clinical Research ( Site 0020) San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06956235, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06956235 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →